Partner Christopher Cain said the Jumpstart Our Business Startups (JOBS) Act will potentially create a diverse investor base that makes non-venture capital funding an effective option for biopharma startups trying to raise money. Cain also said the JOBS Act’s crowdfunding provision can help biopharmas raise supplementary funds for clinical trials, patent applications and company growth that may attract additional investments.
Click here to read the complete article.
People
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.